Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2024.048054
Journal Menu
Special Issues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

ARTICLE

TMED3 promotes prostate cancer via FOXO1a and FOXO3a phosphorylation

XIUWANG WEI1, JIANBO LIANG1, HUANWEN HUANG1, DAMING YANG1, XINXIN WANG1, XIUJIA WANG1, CHANGSHENG CHEN1, KAIQIANG LI1, TAISEN PANG1, BIN HU1, FENGNING WU2,*
1 Department of Urology, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
2 Department of Rehabilitation, The People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China
* Corresponding Author: FENGNING WU. Email: email

Oncology Research https://doi.org/10.32604/or.2024.048054

Received 26 November 2023; Accepted 27 March 2024; Published online 06 May 2024

Abstract

Background: Transmembrane emp24 trafficking protein 3 (TMED3) is associated with the development of several tumors; however, whether TMED3 regulates the progression of prostate cancer remains unclear. Materials and Methods: Short hairpin RNA was performed to repress TMED3 in prostate cancer cells (DU145 cells) and in a prostate cancer mice model to determine its function in prostate cancer in vitro and in vivo. Results: In the present study, we found that TMED3 was highly expressed in prostate cancer cells. In vitro, shTMED3 treatment suppressed the proliferation, invasion, and migration and promoted the apoptosis of DU145 cells. Additionally, the Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis showed a strong correlation between TMED3 and forkhead box O transcription factor (FOXO) pathway. Furthermore, TMED3 inhibition efficiently decreased FOXO1a and FOXO3a phosphorylation. In vivo, TMED3 downregulation suppressed the apoptosis, growth, and metastasis of prostate cancer cells via FOXO1a and FOXO3a. Conclusion: The present findings show that TMED3 participates in the regulation of prostate cancer progression via FOXO1a and FOXO3a phosphorylation, thereby revealing a novel mechanism underlying prostate cancer development and suggesting that TMED3 inhibition may serve as a novel strategy for prostate cancer treatment.

Keywords

Prostate cancer; TMED3; FOXO; Proliferation; Apoptosis

  • 534

    View

  • 86

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link